Sangamo holds a bankruptcy sale; VCs back a China-linked Beam competitor

Sangamo holds a bankruptcy sale; VCs back a China-linked Beam competitor

Eli Lilly and Astellas will be the lead bidders at an auction for Sangamo assets. Elsewhere, an investor syndicate committed $230 million to a gene editing startup and Merck KGaA struck a “build-to-buy” deal.

Gene-editing startup launches with $230 million and a Chinese licensing deal

Serapha Bio is entering a crowded field of firms hoping to develop treatments for the genetic disorder AATD.

Gene Editing Pioneer Sangamo Files for Chapter 11 Bankruptcy; Agrees to Sell Assets

A journey that has lasted more than 30 years for Sangamo Therapeutics, a pioneering gene editing biotech company in the Bay Area, has reached an unwanted milestone as the company filed for Chapter 11 bankruptcy protection. Concurrent with its starting voluntary Chapter 11 proceedings in the U.S. Bankruptcy Court for the District of Delaware, Sangamo simultaneously entered into two separate asset sale agreements: Eli Lilly has agreed to acquire S…

Sangamo’s three-decade run comes to a close as Lilly and Astellas eye assets

Despite being an early player in the gene editing field and developing numerous clinical programs, Sangamo Therapeutics will be selling off its parts without materializing any approved therapies. Sangamo